Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Fresh from the Pipeline
  • Published:

Pregabalin

Nature Reviews Drug Discovery volume 4, pages 455–456 (2005)Cite this article

Abstract

In July 2004, pregabalin (Lyrica; Pfizer) was approved in Europe for the treatment of peripheral neuropathic pain and as an adjunctive therapy for partial seizures in patients with epilepsy. Approval by the US FDA for the management of neuropathic pain associated with diabetic peripheral neuropathy and post-herpetic neuralgia followed in December 2004.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Chemical structures of GABA, gabapentin and pregabalin.

References

  1. Woolf, C. J. & Mannion, R. J. Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet 353, 1959–1964 (1999).

    CAS  PubMed  Google Scholar 

  2. Dworkin, R. H. et al. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch. Neurol. 60, 1524–1534 (2003).

    Article  Google Scholar 

  3. Bryans, J. S. & Wustrow, D. J. 3-substituted GABA analogs with central nervous system activity: a review. Med. Res. Rev. 19, 149–177 (1999).

    Article  CAS  Google Scholar 

  4. Belliotti, T. R. et al. Structure–activity relationships of pregabalin and analogues that target the α2-δ protein. J. Med. Chem. 48, 2294–2307 (2005).

    Article  CAS  Google Scholar 

  5. Bramwell, S. R. et al. The analgesic actions of pregabalin are mediated through its binding to the α2δ-1 subunit of voltage-gated calcium channels. Abs. Soc. Neurosci. Ann. Meeting program 523.19 (2004).

  6. Electronic medicines compendium [online], <http://emc.medicines.org.uk/emc/assets/c/html/displaydoc.asp?documentid=14651> (2004).

  7. Lesser, H. et al. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology 63, 2104–2110 (2004).

    Article  CAS  Google Scholar 

  8. Rosenstock, J. et al. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain 110, 628–638 (2004).

    Article  CAS  Google Scholar 

  9. Richter, R. W. et al. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J. Pain 6, 253–260 (2005).

    Article  CAS  Google Scholar 

  10. Dworkin, R. H. et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 60, 1274–1283 (2003).

    Article  CAS  Google Scholar 

  11. Sabatowski, R. et al. Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. Pain 109, 26–35 (2004).

    Article  CAS  Google Scholar 

  12. Beydoun, A. et al. Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy. Neurology 64, 475–480 (2005).

    Article  CAS  Google Scholar 

  13. Arroyo, S. et al. Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose–response study in adults with partial seizures. Epilepsia 45, 20–27 (2004).

    Article  CAS  Google Scholar 

  14. Drugs@FDA [online], <http://www.fda.gov/cder/foi/appletter/2004/21723ltr.pdf> (2004).

  15. Sawynok, J. et al. Antidepressants as analgesics: an overview of central and peripheral mechanisms of action. J. Psychiatry Neurosci. 26, 21–29 (2001).

    CAS  PubMed  PubMed Central  Google Scholar 

  16. Kalso, E. et al. (eds). Opioid Sensitivity of Chronic Noncancer Pain (IASP, Seattle, 1999).

    Google Scholar 

  17. Woolf, C. J. Pain: moving from symptom control toward mechanism-specific pharmacologic management. Ann. Intern. Med. 140, 441–451 (2004).

    Article  Google Scholar 

  18. Raja, S. N. et al. Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 59, 1015–1021 (2002).

    Article  CAS  Google Scholar 

  19. Gilron, I. et al. Morphine, gabapentin, or their combination for neuropathic pain. N. Engl. J. Med. 352, 1324–1334 (2005).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. the University of Rochester Medical Center, New York, 14642, New York, USA

    Robert H. Dworkin

  2. at Nature Reviews Drug Discovery,

    Peter Kirkpatrick

Authors
  1. Robert H. Dworkin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter Kirkpatrick
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Robert H. Dworkin or Peter Kirkpatrick.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dworkin, R., Kirkpatrick, P. Pregabalin. Nat Rev Drug Discov 4, 455–456 (2005). https://doi.org/10.1038/nrd1756

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd1756

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing